CA-SIRIUS-THERAPEUTICS
2.2.2024 05:01:26 CET | Business Wire | Press release
Sirius Therapeutics, announced it has dosed the first subject in a Phase 1, first-in-human clinical trial in Australia of SRSD107 on January 30th 2024, its next generation siRNA therapeutic targeting coagulation Factor XI (FXI), for the prevention and treatment of thromboembolic disorders. SRSD107 is the second clinical candidate in the company’s portfolio of next generation siRNA therapeutics to treat cardiovascular diseases. The company recently began clinical trials of SRSD101 in China for the treatment of dyslipidemia following IND clearance from the China National Medical Products Administration.
“This trial is based on in vivo studies that demonstrated a nearly 100% reduction of FXI levels for up to 6 months, without bleeding events, after a single subcutaneous dose,” said Dr. Qunsheng Ji, Sirius Therapeutics’ Chief Executive Officer. “The trial will provide an opportunity to evaluate SRSD107’s potential as a differentiated therapeutic for these common disorders globally.”
The SRSD107 Phase 1 study, which is being conducted in healthy volunteers in Australia, will evaluate SRSD107’s safety, tolerability, pharmacokinetics, and pharmacodynamics at single ascending doses and multiple ascending doses.
About Thromboembolic Disorders
Thrombosis, or blood clot formation, is the common underlying mechanism of most cases of myocardial infarction, ischemic stroke, and venous thromboembolism. According to a study in The Lancet of regional and global mortality, thromboembolic disorders are estimated to cause 1 in 4 deaths worldwide1.
About SRSD107
SRSD107 is a novel double-stranded small interfering ribonucleic acid (siRNA). Developed by Sirius Therapeutics, SRSD107 specifically targets coagulation factor XI (FXI) mRNA and inhibits FXI protein expression, thereby blocking the intrinsic coagulation pathway and promoting anticoagulant/anti-thrombotic effects. SRSD107 has been engineered for the potential to enable once or twice-a-year dosing.
About Sirius Therapeutics
Sirius is an innovative, clinical stage biotech company developing next generation siRNA therapy for global markets. We are dedicated to discovering and developing new treatment options for cardiovascular disease patients. Our most advanced products are SRSD107 for the treatment of thromboembolic disorders, and SRSD101 for the treatment of dyslipidemia. Founded in 2021 by a world-class leadership team and investors, Sirius has established an innovative discovery center in the United States and translational medicine center in China. Sirius has raised nearly US$100 million funding to date from OrbiMed, Creacion Ventures, Hankang Capital, Delos Capital, and the leadership team.
[1] Lozano R, Naghavi M, Foreman K, et al. Lancet. 2012;380, 2095-1128.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240201912539/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hytera Introduces PDC580 Dual-Mode Rugged Radio to Support Seamless Communication Across Critical Operations9.7.2026 09:25:00 CEST | Press release
Hytera, a leading global provider of critical communications technologies and solutions, announced the launch of the PDC580 Dual-Mode Rugged Radio, developed for organizations that continue to rely on PMR while expanding broadband communications across increasingly distributed operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708879078/en/ Built to connect LTE and PMR, the Hytera PDC580 brings dual-mode communication into one compact rugged radio. “The transition from narrowband to broadband is not an overnight replacement,” said Arthur Luo, Product Manager of Hytera Smart Terminal BU. “Many organizations will operate mixed communication environments for years to come. The PDC580 is designed to make that transition seamless, allowing teams to stay connected without changing established operational workflows.” Many frontline operations involve personnel working across different locations, departments, and network
LR Invests Over €2 Million in Quality and Growth9.7.2026 09:00:00 CEST | Press release
Global demand for innovative health products continues to grow, and with it the requirements for quality, supply reliability and production capacity. LR Health & Beauty is therefore strengthening its Ahlen headquarters with an investment of more than €2 million, laying the foundation for further growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260709000261/en/ New, state-of-the-art production line in Ahlen, Germany, manufacturing LR 5in1 Beauty Elixir and LR 5in1 Men's Shot. At the heart of the investment is a new, state-of-the-art production line. LR will use it to fully consolidate the manufacturing of its successful 5-in-1 products at its Ahlen headquarters. This includes, among others, the LR 5in1 Beauty Elixir and the LR 5in1 Men’s Shot. At the same time, the new facility creates the conditions for future product innovations in modern nutritional supplement concepts. By bringing the complete production of its 5-in
Robbyant Unveils LingBot-World 2.0: Pioneering Hour-Long Real-Time Generation in World Models9.7.2026 08:52:00 CEST | Press release
Robbyant, an embodied AI company within Ant Group, today announced the open-source release of LingBot-World 2.0 (Infinity). This interactive world model significantly upgraded its world prediction and interactivity capabilities, supporting hour-long continuous generation, 720p/60fps high-definition real-time output, and richer interactive actions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708757367/en/ LingBot-World 2.0: Visual Demo of Real-Time Generation LingBot-World 2.0 also integrates a native agent mechanism, evolving generated worlds from merely watchable and controllable to "sustainably interactive and dynamically evolving", a first in the world model sector. While LingBot-World 1.0 set a benchmark with minutes-level stable generation, version 2.0 pushes the boundaries toward true infinity. The model leverages a Causal Pretraining Paradigm combined with a proprietary MoBA (Mask of Bidirectional Attention) mec
Aidoptation Receives Approval for First Fully Autonomous Driving Tests on Highways in the European Union9.7.2026 08:32:00 CEST | Press release
The Limburg-based autonomous vehicle technology company has received authorization from Belgian authorities to test fully autonomous (Level 4) driving on public highways up to the 120kph speed limit. A first milestone in the EU for testing life-saving autonomous technology in high-speed scenarios where road accidents are most severe. Aidoptation BV, the autonomous vehicle technology company headquartered at DronePort in Sint-Truiden, has received official approval from the Federal Public Service Mobility (FOD) and Transport and the Flemish Agency for Roads and Traffic (AWV) to conduct fully autonomous driving tests on public highways. The permit covers 100 km on the E313 and E314 highways in the province of Limburg, and marks the first time a Level 4 fully autonomous driving system will be tested at highway speeds on public roads in the European Union. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708112110/en/ Our car d
FIFA World Cup™ Fans Embrace Referee View as Lenovo AI Brings Viewers Closer to the Pitch9.7.2026 06:00:00 CEST | Press release
91% of fans say the new broadcast technology has made the FIFA World Cup 2026™ viewing experience more dynamic New international research from Lenovo reveals that technological advancements are fundamentally changing how fans experience the FIFA World Cup 2026™, making viewers feel closer to the action than ever before. According to a survey of football fans across Australia, Canada, India, U.K., U.S., 87% say technology is improving their viewing experience, and 84% report the close-to-action camera perspectives help them feel like they're right there on the pitch. Accelerating this unprecedented view of the game is Referee View, powered by Lenovo AI that gives viewers a first-person look at the match from the referee’s point of view. The research further found: Over three-quarters (76%) of FIFA World Cup™ viewers have seen or heard about Referee View, and 91% say the close-to-action perspective is appealing. 88% say that smooth, stable footage is an important part of viewing sports f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom